Level Four Advisory Services’s Moderna MRNA Stock Holding History

Level Four Advisory Services’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,072	Closed	-$206K	–	834
2024 Q1	$206K	Hold	2,072	–	–	0.01%	714
2023 Q4	$206K	Sell	2,072 -286	-12%	-$24.1K	0.01%	710
2023 Q3	$244K	Sell	2,358 -594	-20%	-$66.3K	0.02%	634
2023 Q2	$359K	Sell	2,952 -127	-4%	-$16.9K	0.02%	571
2023 Q1	$473K	Buy	3,079 +1,093	+55%	+$180K	0.03%	434
2022 Q4	$357K	Buy	+1,986	New	+$325K	0.03%	482
2022 Q3	–	Sell	-1,425	Closed	-$204K	–	569
2022 Q2	$204K	Sell	1,425 -883	-38%	-$126K	0.02%	521
2022 Q1	$398K	Buy	2,308 +272	+13%	+$45.8K	0.03%	455
2021 Q4	$517K	Buy	2,036 +1,354	+199%	+$396K	0.04%	376
2021 Q3	$262K	Sell	682 -1,018	-60%	-$375K	0.03%	410
2021 Q2	$399K	Sell	1,700 -279	-14%	-$49.9K	0.03%	461
2021 Q1	$259K	Sell	1,979 -191	-9%	-$27.7K	0.02%	535
2020 Q4	$227K	Sell	2,170 -4,847	-69%	-$490K	0.02%	533
2020 Q3	$496K	Buy	7,017 +1,186	+20%	+$82.7K	0.04%	351
2020 Q2	$375K	Buy	+5,831	New	+$319K	0.03%	424

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Level Four Advisory Services's MRNA Position: Q2 2024 in Review

Level Four Advisory Services sold out of Moderna (MRNA) in Q2 2024, closing a stake of 2,072 shares — an estimated $206K sold.

Level Four Advisory Services first reported a position in MRNA in Q2 2020 and held it in 15 quarters. The position peaked at $517K in Q4 2021. 954 funds tracked by Wall St. Rank hold MRNA as of Q2 2024.

Level Four Advisory Services reported no remaining Moderna position as of Q2 2024 after selling out during the quarter.
Level Four Advisory Services sold 2,072 Moderna shares in Q2 2024, an estimated $206K.
Level Four Advisory Services first reported a position in Moderna in Q2 2020 and held it in 15 quarters.
Level Four Advisory Services's Moderna position peaked at $517K in Q4 2021.
954 funds tracked by Wall St. Rank held Moderna as of Q2 2024.

Based on Level Four Advisory Services's 13F filing for Q2 2024, filed 9 Aug 2024.